Novartis's LEE011 gets FDA fast track in advanced breast cancer

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review status for Novartis drug LEE011 (ribociclib) as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with letrozole, the Swiss drugmaker said on Tuesday.